Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana. This study is a interventional study that present minimal risks and constraints. The results of the study will allow estimation of COVID-19 virus infection, severity and attack rates, as well as inform public health responses and policy decisions in the French Guiana territory.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
3,541
Blood sample
Centre Hospitalier Andrée Rosemon
Cayenne, French Guiana
Laboratoire de biologie méicale, Institut Pasteur de la Guyane
Cayenne, French Guiana
Laboratoires Eurofins Guyane
Cayenne, French Guiana
Laboratoire de biologie médicale de Kourou
Kourou, French Guiana
Measure of the COVID-19 immunity of the population
The COVID-19 immunity of the population will be assessed by evaluating the anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies
Time frame: 1 year
Evaluation of the level of asymptomatic and pauci-symptomatic infections
The proportion of asymptomatic and pauci-symptomatic infections will be measured in the population
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni
Saint-Laurent-du-Maroni, French Guiana